Family Office Of America (FOFA) EBITDA Margin (2026)
Family Office Of America (FOFA) reported EBITDA Margin of 35.1% for Q1 2026.
Family Office Of America (FOFA) EBITDA Margin (2026) Analysis & Trends
Family Office Of America (FOFA) has 1 years of EBITDA Margin data on file, last reported at 35.1% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Family Office Of America | 27.22 Mn | 26.88 Mn | 783,126.00 | 35.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.10% |